Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer

Abstract

The presence of serum APA is unlikely to be a strong prognostic indictor for prostate cancer on an individual basis as false positives will occur. However, such immune reactions which may be associated with PSA in cancer patients are in any case of interest in both the biology of prostate cancer and male fertility. The source of prostasomal antigen may be of critical importance to the outcome of the assay. However, immune reactions to prostasomes may be of considerable interest and warrant continued investigation.

Prostasomes as a source of diagnostic biomarkers for prostate cancer

“…Urine-based tests of the immune system to produce prostasome-directed autoantibodies, which can be detected in blood from PCa patients (53,60). However, there is no consensus on whether titers of prostasomedirected antibodies correlate with PCa grade or metastasis (54,62,63), leaving little evidence that prostasome-specific antibodies can be used as reliable prognostic markers for PCa.…”

Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis

“…This process induces the adaptive immune system to produce prostasome-directed autoantibodies, which can be isolated by PCa patients' blood (39,41). However, antibodies against prostasome cannot be quantified and their correlation with PCa grade or metastasis it is not possible (40,45), showing the low efficacy of prostasome-specific antibodies as reliable prognostic markers for PCa (46).…”